Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate

 
• By Joseph Haas
  
business documents accounting with calculator and magnifying glass. concept for financial
Gilead's HIV franchise is flourishing, while cancer cell therapy is sluggish
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business